← Back to the fund pageUse your browser's print dialog and choose “Save as PDF”. A4, two pages.
InvestVerdict
BANK OF INDIA LARGE & MID CAP FUND
Direct Plan · Growth · Mid Cap · Scheme code 119350
NAV₹110.0600as on 28 Aug 2026
Fund houseBank of India Mutual Fund
CategoryMid Cap
Plan & optionDirect · Growth
History13.7 years
Returns (%)
1M
3M
6M
1Y
3Y
5Y
7Y
10Y
Launch
This scheme
1.81
6.03
5.67
11.69
15.80
13.46
18.09
13.82
13.94
Nifty Midcap 150 benchmark
1.72
4.38
7.84
13.13
17.93
18.11
—
—
22.88
Mid Cap category median
—
—
—
10.21
19.84
17.23
—
17.08
—
Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
15.9%
0.59
0.80
0.80
-2.31%
-37.9%
89.67
Nifty Midcap 150 benchmark
18.3%
0.62
0.83
—
—
-37.2%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
83 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
623
-20.2%
13.2%
70.3%
20%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
InvestVerdict
BANK OF INDIA LARGE & MID CAP FUND
Direct Plan · Growth
Allocation
By asset
Equity
95.69%
Cash & Equivalents
4.30%
Debt
0.01%
By market cap
Large Cap
38.82%
Mid Cap
39.32%
Small Cap
18.78%
Unclassified
0.01%
Concentration
Number of stocks
51
Top 5 stocks
26.50%
Top 10 stocks
42.47%
Top 20 stocks
64.57%
Largest holding
8.11%
Largest sector
Banks 18.42%
Effective stocks
34.1
Cash
4.30%
InvestVerdict
BANK OF INDIA LARGE & MID CAP FUND
Direct Plan · Growth · holdings
Top 18 holdings
#
Company
Sector
% of fund
1
—
Banks
8.11%
2
—
Petroleum Products
6.34%
3
—
Consumer Durables
4.33%
4
—
4.23%
5
—
Retailing
4.18%
6
—
Banks
3.54%
7
—
Construction
3.48%
8
—
Pharmaceuticals & Biotechnology
3.48%
9
—
Banks
3.34%
10
—
Gas
2.88%
11
—
Financial Technology (Fintech)
2.79%
12
—
Pharmaceuticals & Biotechnology
2.50%
13
—
Diversified FMCG
2.44%
14
—
Banks
2.43%
15
—
Entertainment
2.36%
16
—
Pharmaceuticals & Biotechnology
2.33%
17
—
IT - Software
2.27%
18
—
Retailing
2.09%
Sector split
Banks
18.42%
Pharmaceuticals & Biotechnology
11.74%
Retailing
7.75%
Consumer Durables
7.36%
Petroleum Products
6.34%
4.23%
Construction
3.57%
Financial Technology (Fintech)
3.27%
Auto Components
3.00%
Finance
2.98%
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹852,054
₹252,054
14.01%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 31 Aug 2026.